Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Horm
de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.
| Condition(s) | Prostate Cancer, Radiotherapy Side Effect, Metastatic Cancer |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested. |
| Who can participate | Inclusion Criteria: 1. Signed Informed Consent 2. Histological confirmed prostate cancer 3. Indication for early palliative radiation therapy of low burden metastatic prostate cancer. Low burden as defined by modified CHAARTED trial criteria to maximum 4 skeletal mets at any site and/or any number of lymph nodes 4. baseline E-PROM Exclusion Criteria: 1. High burden metastatic prostate cancer including all with visceral mets. 2. Unable to comply with study procedures. 3. Other diseases or medication that will put the patient at risk for more toxicity from radiotherapy 4. Radiation treatment start later than nine months after the prostate cancer diagnosis. 5. Severe micturition problems, IPSS \> 20 ( International Prostate Symptom Score) |
| Ages | 18 Years |
| Sex | Male |
| Lead sponsor | Umeå University |
| Locations | Umeå, Sweden |
| Start date | 2022-10-31 |
| NCT ID | NCT04612907 |
| Official listing | https://clinicaltrials.gov/study/NCT04612907 |